5 days ago
Cohance to invest $10 million to expand capabilities of U.S. arm, ₹23 cr. in new facility at Hyderabad
Global contract research, development and manufacturing organisation Cohance Lifesciences on Tuesday said it will invest $10 million to expand cGMP bioconjugation capabilities at its U.S based subsidiary NJ Bio.
In another announcement, Cohance said it will be investing ₹23 crore on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad.
The investment in the U.S. will advance its global expansion in niche technology-led modalities, enhancing ability to support innovators from early development through late-phase clinical supply. The build-out of a cGMP compliant bioconjugation suite at NJ Bio's Princeton, New Jersey facility strengthens the company's capabilities to deliver fully integrated antibody-drug conjugate (ADC) solutions, Cohance said.
The new suite, designed to handle high-potent drug substances, will have the flexibility to manufacture up to 2 kg of ADCs. The facility is expected to be operational by the end of Q4FY26, with related bioconjugation work commencing thereafter.
On the investment on the cGMP Oligonucleotide facility in Hyderabad, Cohance (formerly known as Suven Pharma) said the facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. It will enable the company to take high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics.
Customer engagements are underway, with audits planned in coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence by December. Cohance said the two investments are part of planned capacity expansion programme across high-growth modalities enhancing its ability to serve global innovators from early development to commercial supply.
